ACVR2B and fibrodysplasia ossificans progressiva: The fact that a low rapamycin concentration promoted cell survival and production of the ACVR2B-Fc fusion protein and synergistically reduced primary and recurrent HO indicated that the combination of stem cell therapy and immunosuppressants may benefit patients with FOP by reducing recurrent HO caused by surgical removal of the primary lesion.